To our knowledge, this is the first report focused on the accuracy of CNB samples in evaluating HER2-Low status in a large cohort of treatment-naïve early breast cancer patients, which demonstrated a high discordance rate of 23.13% in HER2-Negative tumors. This evidence concerns the gene ERBB2 and breast carcinoma.